203 related articles for article (PubMed ID: 19878629)
1. Spotlight on alemtuzumab.
Jones JL; Coles AJ
Int MS J; 2009 Sep; 16(3):77-81. PubMed ID: 19878629
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab.
Bates D
Int MS J; 2009 Sep; 16(3):75-6. PubMed ID: 19899240
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
; Coles AJ; Compston DA; Selmaj KW; Lake SL; Moran S; Margolin DH; Norris K; Tandon PK
N Engl J Med; 2008 Oct; 359(17):1786-801. PubMed ID: 18946064
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.
Brown JW; Coles AJ
Drug Des Devel Ther; 2013; 7():131-8. PubMed ID: 23494602
[TBL] [Abstract][Full Text] [Related]
5. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Jones JL; Anderson JM; Phuah CL; Fox EJ; Selmaj K; Margolin D; Lake SL; Palmer J; Thompson SJ; Wilkins A; Webber DJ; Compston DA; Coles AJ
Brain; 2010 Aug; 133(Pt 8):2232-47. PubMed ID: 20659956
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
Graves J; Galetta SL; Palmer J; Margolin DH; Rizzo M; Bilbruck J; Balcer LJ
Mult Scler; 2013 Sep; 19(10):1302-9. PubMed ID: 23459567
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
[TBL] [Abstract][Full Text] [Related]
9. The outlook for alemtuzumab in multiple sclerosis.
Williams T; Coles A; Azzopardi L
BioDrugs; 2013 Jun; 27(3):181-9. PubMed ID: 23558379
[TBL] [Abstract][Full Text] [Related]
10. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Hersh CM; Cohen JA
Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
[TBL] [Abstract][Full Text] [Related]
13. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis.
Hirst CL; Pace A; Pickersgill TP; Jones R; McLean BN; Zajicek JP; Scolding NJ; Robertson NP
J Neurol; 2008 Feb; 255(2):231-8. PubMed ID: 18283404
[TBL] [Abstract][Full Text] [Related]
14. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
15. Multiple lessons for multiple sclerosis.
Hauser SL
N Engl J Med; 2008 Oct; 359(17):1838-41. PubMed ID: 18946071
[No Abstract] [Full Text] [Related]
16. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
Hill-Cawthorne GA; Button T; Tuohy O; Jones JL; May K; Somerfield J; Green A; Giovannoni G; Compston DA; Fahey MT; Coles AJ
J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):298-304. PubMed ID: 22056965
[TBL] [Abstract][Full Text] [Related]
17. Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
Klotz L; Meuth SG; Wiendl H
Clin Immunol; 2012 Jan; 142(1):25-30. PubMed ID: 21550857
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis.
Fox EJ
Expert Rev Neurother; 2010 Dec; 10(12):1789-97. PubMed ID: 21091310
[TBL] [Abstract][Full Text] [Related]
19. [Recent advances in the pathogenesis and immunotherapy of multiple sclerosis].
Gold R; Rieckmann P
Nervenarzt; 2007 Sep; 78 Suppl 1():15-24; quiz 25. PubMed ID: 17668159
[TBL] [Abstract][Full Text] [Related]
20. [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].
Warnke C; Kieseier BC; Zettl U; Hartung HP
Nervenarzt; 2009 Apr; 80(4):468-74. PubMed ID: 19296065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]